인공 췌장 디바이스 시스템 시장 : 구성 요소별, 적응증별, 디바이스 유형별, 치료법별, 시스템 유형별, 최종 사용자별, 판매 채널별 - 세계 시장 예측(2026-2032년)

The Artificial Pancreas Device System Market is projected to grow by USD 686.27 million at a CAGR of 8.74% by 2032.

Artificial Pancreas Device System Market Overview

Artificial pancreas device systems (APDS), also known as automated insulin delivery or hybrid closed-loop systems, combine a continuous glucose monitor, insulin pump, and dosing algorithm to automate insulin adjustments for people living with insulin-dependent diabetes. These systems are moving diabetes management from reactive self-care toward predictive, data-driven therapy that can improve time in range, reduce hypoglycemia exposure, and lessen the burden of manual dosing decisions.

Demand is supported by the rising global diabetes burden, strong clinical evidence for closed-loop insulin delivery, and expanding regulatory pathways for interoperable diabetes devices. The International Diabetes Federation reports that hundreds of millions of adults live with diabetes worldwide, while type 1 diabetes continues to create a durable need for advanced insulin delivery technologies. For manufacturers, payers, providers, and digital health partners, the artificial pancreas device system market is increasingly defined by clinical outcomes, usability, reimbursement access, cybersecurity, algorithm performance, and equitable patient access.

Transformative Shifts in the Artificial Pancreas Landscape

The artificial pancreas device system landscape is being reshaped by the shift from standalone pumps and glucose sensors to interoperable diabetes technology ecosystems. Regulatory categories such as integrated continuous glucose monitors and alternate controller enabled insulin pumps have encouraged modular innovation, allowing qualified devices to communicate safely and support more flexible product combinations.

Another major shift is the movement from specialist-only adoption toward broader diabetes care pathways. Pediatric use, telehealth follow-up, remote monitoring, and pharmacy-supported education are expanding access, while payers increasingly evaluate automated insulin delivery based on measurable improvements in time in range, hypoglycemia reduction, hospital utilization, and long-term diabetes complication risk. At the same time, industry participants face pressure to lower device complexity, improve sensor wearability, extend infusion reliability, and support diverse populations historically underrepresented in diabetes technology trials.

Cumulative Impact of AI on Automated Insulin Delivery

Artificial intelligence is amplifying the value of artificial pancreas device systems by improving glucose forecasting, insulin dosing recommendations, anomaly detection, and personalization. Modern algorithms increasingly account for insulin-on-board, glucose trends, meal timing, exercise, sleep, stress, illness, and behavioral variability, enabling more adaptive therapy than fixed basal schedules.

The cumulative impact of AI extends beyond insulin automation. Machine learning can support sensor signal refinement, infusion-set failure detection, clinical decision support, population-level risk stratification, and real-world evidence generation from connected-device data. However, responsible AI deployment requires transparent validation, bias assessment, post-market monitoring, human factors testing, privacy safeguards, and cybersecurity controls, particularly because APDS decisions can directly affect patient safety.

Key Regional Insights Across Global APDS Markets

North America remains a leading region for artificial pancreas device system adoption due to early regulatory clearances, strong endocrinology and diabetes education networks, commercial and public payer coverage pathways, and a mature ecosystem of continuous glucose monitor and insulin pump users. The United States continues to anchor innovation and clinical adoption, while Canada benefits from provincial reimbursement progress, established diabetes care infrastructure, and growing awareness of automated insulin delivery benefits.

Europe is shaped by CE marking requirements, the European Medical Device Regulation, national health technology assessment processes, and increasing reimbursement recognition for hybrid closed-loop systems. The United Kingdom, Germany, France, Italy, and Spain are important adoption centers, with payer scrutiny focused on clinical outcomes, safety, usability, and budget impact. Asia-Pacific offers significant long-term patient opportunity because of the scale of diabetes prevalence in China and India, combined with high technology readiness, specialist capacity, and connected-device adoption in Japan, South Korea, and Australia.

Latin America shows rising interest in Brazil and Mexico, supported by expanding diabetes diagnosis and private healthcare access, but adoption remains constrained by reimbursement gaps, device affordability, and uneven access to endocrinology services. The Middle East, particularly affluent Gulf markets, is adopting premium diabetes technologies through advanced hospital systems, high diabetes awareness, and government investment in digital health. Africa's adoption is more limited by affordability, insulin access, supply-chain resilience, and clinical infrastructure, creating opportunities for lower-cost, durable, mobile-enabled, and service-supported APDS solutions.

Key Group Insights for APDS Commercial Strategy

Within ASEAN, artificial pancreas device system adoption is uneven, with Singapore and Malaysia demonstrating stronger digital health readiness, specialist access, and private insurance support than lower-income markets where out-of-pocket costs remain a barrier. Local partnerships, distributor capability, physician training, and diabetes education programs are essential for scaling automated insulin delivery across diverse health systems.

The GCC represents a high-value market group because of elevated diabetes prevalence, government investment in specialty care, modern hospital infrastructure, and demand for connected health solutions. The European Union supports structured adoption through clinical evidence standards, privacy regulation, coordinated medical device oversight, and national reimbursement assessment, while BRICS economies combine large diabetes populations with price sensitivity, localization priorities, and growing domestic medtech capabilities.

G7 markets are central to premium artificial pancreas innovation, reimbursement evidence generation, clinical guideline development, and early adoption of interoperable diabetes technology platforms. NATO countries, while not a healthcare market bloc, share overlapping priorities in resilient medical supply chains, cybersecurity, trusted digital infrastructure, and continuity of care, which are increasingly relevant for connected insulin delivery devices and AI-enabled diabetes management systems.

Key Country Insights in Artificial Pancreas Adoption

The United States is one of the most influential artificial pancreas device system markets, supported by defined regulatory pathways, advanced endocrinology networks, broad continuous glucose monitor adoption, diabetes technology literacy, and payer experience with insulin pump reimbursement. Canada offers steady adoption through provincial coverage improvements and strong clinical infrastructure, while Mexico and Brazil provide sizable diabetes populations but require affordability strategies, payer engagement, local education, and differentiated channel models.

In Europe, the United Kingdom's national health technology guidance has strengthened the case for hybrid closed-loop therapy in eligible people with type 1 diabetes, while Germany benefits from advanced reimbursement mechanisms, digital health readiness, and specialist-led adoption. France, Italy, and Spain are expanding access through national and regional evaluation processes, with adoption influenced by payer criteria, diabetes center capacity, and clinician training. Russia remains more constrained by geopolitical factors, procurement complexity, regulatory navigation, and supply-chain uncertainty.

China and India represent substantial long-term opportunities due to large diabetes populations and expanding digital health infrastructure, but access depends on pricing, localization, regulatory navigation, physician training, and patient affordability. Japan, Australia, and South Korea show stronger readiness for advanced diabetes technology, supported by high healthcare standards, connected-device adoption, established specialist care pathways, and growing recognition of automated insulin delivery for improving glycemic outcomes and quality of life.

Actionable Recommendations for APDS Industry Leaders

Industry leaders should prioritize clinically validated interoperability, simplified onboarding, and evidence generation that demonstrates improvements in time in range, A1c, hypoglycemia reduction, treatment satisfaction, sleep quality, and quality of life. Product roadmaps should emphasize smaller devices, longer sensor wear, faster warm-up times, improved infusion reliability, lower alarm burden, accessible mobile interfaces, and safe algorithm performance across pediatric, adult, pregnancy, and high-risk user groups.

Commercial teams should build payer-specific value dossiers, support outcomes-based contracting where feasible, and invest in clinician and patient education to reduce adoption friction. Organizations should also strengthen cybersecurity, comply with evolving privacy and medical device regulations, expand multilingual and culturally appropriate support, improve supply-chain resilience, and design pricing and service models that improve access in emerging markets without compromising premium innovation in advanced healthcare systems.

Research Methodology

This executive summary is based on a structured research methodology combining secondary research, regulatory review, clinical literature assessment, reimbursement analysis, and market triangulation. Sources considered include public information from health agencies, diabetes associations, medical device regulators, peer-reviewed clinical studies, reimbursement bodies, healthcare technology assessment agencies, device labeling, clinical guidelines, and technology standards relevant to connected insulin delivery.

Insights were validated by comparing adoption drivers across regions, assessing product and regulatory milestones, and evaluating demand indicators such as diabetes prevalence, type 1 diabetes care needs, continuous glucose monitor penetration, insulin pump access, reimbursement maturity, provider readiness, cybersecurity expectations, and digital health infrastructure. The methodology emphasizes verified, evidence-based interpretation and avoids unsupported market estimates, market sizing, market share, or forecasting claims.

Conclusion

Artificial pancreas device systems are becoming a core pillar of modern diabetes care as connected sensors, insulin pumps, and adaptive algorithms converge into safer, more personalized, and less burdensome therapy. The next phase of the artificial pancreas device system market will be shaped by interoperability, AI-enabled optimization, payer evidence, cybersecurity, usability, and equitable access across advanced and emerging healthcare systems.

Organizations that combine clinical credibility with scalable digital infrastructure, strong regulatory execution, resilient supply chains, and patient-centered design will be best positioned to advance adoption. As healthcare systems prioritize outcomes, chronic disease efficiency, and connected care, APDS technologies are expected to remain central to the future of insulin-dependent diabetes management.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Artificial Pancreas Device System Market, by Component

• 7.1. Control Algorithms
  • 7.1.1. Model Predictive Control
  • 7.1.2. Proportional Integral Derivative Control
• 7.2. Display Devices
  • 7.2.1. Traditional Handheld Devices
  • 7.2.2. Wearable Display Devices
• 7.3. Insulin Pumps
  • 7.3.1. Patch Pumps
  • 7.3.2. Tubed Pumps
  • 7.3.3. Tubeless Pumps
• 7.4. Sensors
  • 7.4.1. Glucose Sensors
  • 7.4.2. Insulin Sensors

8. Artificial Pancreas Device System Market, by Indication

• 8.1. Type 1 Diabetes
• 8.2. Type 2 Diabetes

9. Artificial Pancreas Device System Market, by Device Type

• 9.1. Closed Loop Systems
• 9.2. Hybrid Closed Loop Systems
• 9.3. Open Loop Systems

10. Artificial Pancreas Device System Market, by Treatment Type

• 10.1. Insulin-Only Systems
• 10.2. Bi-Hormonal Systems
• 10.3. Hybrid Hormonal Systems

11. Artificial Pancreas Device System Market, by System Type

• 11.1. Fully Automated Systems
• 11.2. Semi-Automated Systems
• 11.3. Manual Systems

12. Artificial Pancreas Device System Market, by End User

• 12.1. Diagnostic Centers
• 12.2. Homecare Settings
• 12.3. Hospitals
• 12.4. Medical Research Institutes

13. Artificial Pancreas Device System Market, by Sales Channel

• 13.1. Direct Sales
• 13.2. Distributors
• 13.3. Online Retailers

14. Artificial Pancreas Device System Market, by Region

• 14.1. Asia-Pacific
• 14.2. North America
• 14.3. Latin America
• 14.4. Europe
• 14.5. Middle East
• 14.6. Africa

15. Artificial Pancreas Device System Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Artificial Pancreas Device System Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025

18. Company Profiles

• 18.1. Abbott Laboratories
• 18.2. Admetsys Corporation
• 18.3. B. Braun Melsungen AG
• 18.4. Beta Bionics, Inc.
• 18.5. Bigfoot Biomedical Inc.
• 18.6. Cellnovo Group SA
• 18.7. Defymed SAS
• 18.8. Dexcom, Inc.
• 18.9. Diabeloop SA
• 18.10. DreaMed Diabetes Ltd.
• 18.11. Eli Lilly and Company
• 18.12. F. Hoffmann-La Roche Ltd
• 18.13. Glooko, Inc.
• 18.14. Glytec, LLC
• 18.15. Inreda Diabetic B.V.
• 18.16. Insulet Corporation
• 18.17. Johnson & Johnson
• 18.18. Medtronic PLC
• 18.19. Medtrum Technologies Inc.
• 18.20. MicroTech Medical Co., Ltd.
• 18.21. NIKKISO Co., Ltd.
• 18.22. Pancreum, Inc.
• 18.23. Renfrew Group International
• 18.24. Securecell AG
• 18.25. Senseonics Holdings, Inc.
• 18.26. Sequel Med Tech, LLC
• 18.27. SOOIL Development Co., Ltd.
• 18.28. Tandem Diabetes Care, Inc.
• 18.29. The Menarini Group